simplyStocks
Gilead Sciences
GILD · NASDAQBiopharmaceuticals
The economic chain
Follow the chain left → right, from inputs to end demand. Tap any company to trace its links.
Raw inputs
Equipment
Foundry
Chip design
Software
AI demand
—
Company details
Market cap
~$155B
P/E ratio
~18×
Div yield
~3.0%
EPS (2025)
$6.78
Net income
~$8.5B
Rev. growth
+2%
Revenue (2025)
$29.4B
2026 guidance
~$29.6–30.0B
In plain English
Gilead is the company that turned HIV from a death sentence into a once-a-day pill — Biktarvy alone is one of the world's best-selling medicines, and its new long-acting shot (lenacapavir / Yeztugo) can prevent HIV with two injections a year. On the back of that antiviral cash machine it has spent ~$40B buying its way into cancer: CAR-T cell therapy (Kite) and the Trodelvy antibody-drug conjugate (Immunomedics).
In simple terms
What Gilead Sciences really sells
Gilead is the company that turned HIV from a death sentence into a once-a-day pill — Biktarvy alone is one of the world's best-selling medicines, and its new long-acting shot (lenacapavir / Yeztugo) can prevent HIV with two injections a year. On the back of that antiviral cash machine it has spent ~$40B buying its way into cancer: CAR-T cell therapy (Kite) and the Trodelvy antibody-drug conjugate (Immunomedics).
Tip · Click any company in the map to learn — in one sentence — what it actually does and why it matters.
Risk read
SteadierMore speculative
Why this rating?